Tag

Bluebird

All articles tagged with #bluebird

business1 month ago•18 min saved

AST SpaceMobile expands global footprint with NZ gateway approval and Texas manufacturing push

AST SpaceMobile secured New Zealand gateway authorization, completed a Québec ground station with Bell Canada to support direct-to-device service, received BlueBird 11 at Cape Canaveral with BlueBirds 12 and 13 slated for an August launch, and is weighing a $150 million Texas manufacturing expansion in Midland—signaling progress toward a global network while underscoring risks from cash burn and execution as the rollout scales.

via Yahoo Finance|

#ast-spacemobile #asts #bluebird

space2 months ago•4 min saved

SpaceX lofts three BlueBird satellites to boost AST SpaceMobile network

SpaceX launched three Block 2 BlueBird satellites (BlueBird 8, 9, 10) for AST SpaceMobile on a Falcon 9 from Cape Canaveral, deploying BlueBird 10 about 54.5 minutes after liftoff and the other two roughly five minutes apart; booster B1077 landed on the drone ship 'A Shortfall of Gravitas' marking another SpaceX booster recovery, while the trio aims to enable space-based broadband for unmodified smartphones around the world.

via Spaceflight Now|

#ast-spacemobile #bluebird #falcon-9

technology6 months ago•6 min saved

AST SpaceMobile Secures $30M SDA Contract to Demonstrate Direct-to-Device Satellite Communications

AST SpaceMobile won a roughly $30 million OTA prime contract from the U.S. Space Development Agency under HALO Europa Track 2 to rapidly demonstrate resilient, direct-to-device tactical satellite communications using its BlueBird LEO constellation, leveraging a software-defined bent-pipe architecture to integrate with existing military radios and support defense applications.

via Business Wire|

#ast-spacemobile #bluebird #halo-europa

healthcare3 years ago•6 min saved

Bluebird submits sickle cell gene therapy for FDA approval, following Vertex and CRISPR Therapeutics.

Bluebird bio has submitted an application for its sickle cell gene therapy, lovo-cel, to the FDA for potential approval in patients with sickle cell disease who are 12 or older and have experienced serious attacks associated with the disease. In clinical trials, 28 of 29 patients who received the therapy had no severe attacks in the two years of the study compared to an average of 3.5 events in the two years prior to enrolling in the study. This submission sets up a race with Vertex and CRISPR Therapeutics, who have also submitted their own sickle cell therapy application to the agency.

via Endpoints News|

#bluebird #clinical-trials #fda